ARS Pharmaceuticals secures health Canada approval for needle-free epinephrine
ARS Pharmaceuticals (NASDAQ:SPRY) has received Health Canada approval for neffy 2 mg, marking the first time a needle-free epinephrine delivery system has been authorized for the emergency treatment of severe allergic reactions in Canada.





-640x360.webp&w=3840&q=75)




